← Back to Search

enVista Aspire intraocular lens (IOL) for Pseudoaphakia

N/A
Recruiting
Research Sponsored by Bausch & Lomb Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 90 to day 180 after second eye implantation
Awards & highlights
No Placebo-Only Group

Summary

A Study to Evaluate the enVista® Aspire (EA) intraocular lens in Subjects Undergoing Cataract Extraction

Eligible Conditions
  • Pseudoaphakia
  • Cataract

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 90 to day 180 after second eye implantation
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 90 to day 180 after second eye implantation for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean binocular BCDVA (logMAR) at Visit 1

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: enVista Aspire intraocular lens (IOL)Experimental Treatment1 Intervention
Subjects bilaterally implanted with enVista Aspire EA IOLs.

Find a Location

Who is running the clinical trial?

Bausch & Lomb IncorporatedLead Sponsor
257 Previous Clinical Trials
58,130 Total Patients Enrolled
~67 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top